Relmada Therapeutics (RLMD)
(Delayed Data from NSDQ)
$2.77 USD
-0.03 (-1.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.74 -0.03 (-1.08%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Relmada Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 104 | 161 | 126 | 61 | 0 |
Income After Depreciation & Amortization | -104 | -161 | -126 | -61 | 0 |
Non-Operating Income | 5 | 4 | 0 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -99 | -157 | -126 | -59 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -99 | -157 | -126 | -59 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -99 | -157 | -126 | -59 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -104 | -161 | -126 | -61 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -104 | -161 | -126 | -61 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.10 | 29.63 | 17.55 | 15.59 | 6.31 |
Diluted EPS Before Non-Recurring Items | -3.28 | -5.30 | -7.16 | -3.81 | -2.16 |
Diluted Net EPS (GAAP) | -3.28 | -5.30 | -7.16 | -3.81 | -2.76 |
Fiscal Year end for Relmada Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 18.82 | 22.99 | 26.83 | 22.69 | 26.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | -18.82 | -22.99 | -26.83 | -22.69 | -26.03 |
Non-Operating Income | 1.05 | 1.16 | 1.66 | 0.69 | 0.72 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -17.77 | -21.83 | -25.17 | -22.00 | -25.30 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -17.77 | -21.83 | -25.17 | -22.00 | -25.30 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -17.77 | -21.83 | -25.17 | -22.00 | -25.30 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 30.17 | 30.13 | 30.10 | 30.10 | 30.10 |
Diluted EPS Before Non-Recurring Items | -0.59 | -0.72 | -0.84 | -0.73 | -0.84 |
Diluted Net EPS (GAAP) | -0.59 | -0.72 | -0.84 | -0.73 | -0.84 |